GLOBAL SAFETY OF BENRALIZUMAB: PHARMACOVIGILANCE ANALYSIS OF SPONTANEOUS REPORT DATA

Ensuring drug safety is one of the key areas of modern medicine and pharmacy. Recent studies and publications confirm the long-term effectiveness and safety of using benralizumab. However, when making clinical decisions, it is important to consider the risks associated with biological therapy in order to provide adequate consultations for patients and effectively monitor potential adverse reactions. This article examines serious and significant adverse reactions associated with the use of benralizumab, as well as an analysis of the World Health Organization's global database, VigiBase, regarding adverse reactions to benralizumab. The data obtained on adverse reactions serve as a theoretical basis for improving the pharmacovigilance and drug monitoring system in Russia, presenting significant practical value for physicians, researchers, and healthcare professionals.